Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review

Cystic fibrosis (CF) is a rare, progressive, multi-organ genetic disease. Ivacaftor, a small-molecule CF transmembrane conductance regulator modulator, was the first medication to treat the underlying cause of CF. Since its approval, real-world clinical experience on the use of ivacaftor has been do...

Descripción completa

Detalles Bibliográficos
Autores principales: Duckers, Jamie, Lesher, Beth, Thorat, Teja, Lucas, Eleanor, McGarry, Lisa J., Chandarana, Keval, De Iorio, Fosca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038673/
https://www.ncbi.nlm.nih.gov/pubmed/33917386
http://dx.doi.org/10.3390/jcm10071527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038673/
https://www.ncbi.nlm.nih.gov/pubmed/33917386
http://dx.doi.org/10.3390/jcm10071527

Ejemplares similares